1-10 of 10
Danny Rischin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO-003: Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009

Kevin J. Harrington, Hye Ryun Kim, Sebastien Salas, Marc Oliva, Robert Metcalf, Mogens Bernsdorf, Ji-Won Kim, Ezra E. W. Cohen, Lillian Siu, Danny Rischin, Lisa Licitra, Jan Vermorken, Quynh Le, Makoto Tahara, Jean-Pascal Machiels, Karen O'Hara, Kumudu Pathiraja, Burak Gumuscu, Behzad Bidadi, Barbara Burtness
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-003.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-003
Published: 15 September 2023
View article titled, Abstract PO-003: Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009
Journal Articles

Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason A. Chesney, Beatriz Castelo Fernandez, Danny Rischin, Ezra E.W. Cohen, Hoi-Shen Radcliffe, Burak Gumuscu, Jonathan Cheng, Wendy Snyder, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5153–5161.
https://doi.org/10.1158/1078-0432.CCR-20-1170
Published: 01 October 2020
View article titled, Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
Open the PDF for Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study in another window
Includes: Supplementary data
Journal Articles

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition

George Au-Yeung, Franziska Lang, Walid J. Azar, Chris Mitchell, Kate E. Jarman, Kurt Lackovic, Diar Aziz, Carleen Cullinane, Richard B. Pearson, Linda Mileshkin, Danny Rischin, Alison M. Karst, Ronny Drapkin, Dariush Etemadmoghadam, David D.L. Bowtell
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (7): 1862–1874.
https://doi.org/10.1158/1078-0432.CCR-16-0620
Published: 02 April 2017
View article titled, Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
Open the PDF for Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition in another window
Includes: Supplementary data
Journal Articles

Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer

Dariush Etemadmoghadam, George Au-Yeung, Meaghan Wall, Chris Mitchell, Maya Kansara, Elizabeth Loehrer, Crisoula Batzios, Joshy George, Sarah Ftouni, Barbara A. Weir, Scott Carter, Irma Gresshoff, Linda Mileshkin, Danny Rischin, William C. Hahn, Paul M. Waring, Gad Getz, Carleen Cullinane, Lynda J. Campbell, David D. Bowtell
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (21): 5960–5971.
https://doi.org/10.1158/1078-0432.CCR-13-1337
Published: 31 October 2013
View article titled, Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <em>CCNE1</em>-Amplified Ovarian Cancer
Open the PDF for Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <em>CCNE1</em>-Amplified Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer

Quynh-Thu Le, Richard Fisher, Kelly S. Oliner, Richard J. Young, Hongbin Cao, Christina Kong, Edward Graves, Rodney J. Hicks, Grant A. McArthur, Lester Peters, Brian O'Sullivan, Amato Giaccia, Danny Rischin
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1798–1807.
https://doi.org/10.1158/1078-0432.CCR-11-2094
Published: 14 March 2012
View article titled, Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer
Open the PDF for Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial

Annette M. Lim, Danny Rischin, Richard Fisher, Hongbin Cao, Kathleen Kwok, Daniel Truong, Grant A. McArthur, Richard J. Young, Amato Giaccia, Lester Peters, Quynh-Thu Le
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 301–307.
https://doi.org/10.1158/1078-0432.CCR-11-2295
Published: 02 January 2012
View article titled, Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial
Open the PDF for Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial in another window
Journal Articles

Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation

Danny Rischin, David C. Bibby, Geoff Chong, Gabriel Kremmidiotis, Annabell F. Leske, Clayton A. Matthews, Shirley S. Wong, Mark A. Rosen, Jayesh Desai
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5152–5160.
https://doi.org/10.1158/1078-0432.CCR-11-0937
Published: 31 July 2011
View article titled, Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Open the PDF for Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation in another window
Includes: Supplementary data
Journal Articles

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Michael S. Anglesio, Joshy George, Hagen Kulbe, Michael Friedlander, Danny Rischin, Charlotte Lemech, Jeremy Power, Jermaine Coward, Prue A. Cowin, Colin M. House, Probir Chakravarty, Kylie L. Gorringe, Ian G. Campbell, Australian Ovarian Cancer Study Group, Aikou Okamoto, Michael J. Birrer, David G. Huntsman, Anna de Fazio, Steve E. Kalloger, Frances Balkwill, C. Blake Gilks, David D. Bowtell
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2538–2548.
https://doi.org/10.1158/1078-0432.CCR-10-3314
Published: 14 April 2011
View article titled, IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
Open the PDF for IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Imatinib in Patients with Small Cell Lung Cancer

Bruce E. Johnson, Thomas Fischer, Berthold Fischer, David Dunlop, Danny Rischin, Sandra Silberman, Mildred Ortu Kowalski, Deanne Sayles, Sasa Dimitrijevic, Christopher Fletcher, Jason Hornick, Ravi Salgia, Thierry Le Chevalier
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 5880–5887.
Published: 15 December 2003
View article titled, Phase II Study of Imatinib in Patients with Small Cell Lung Cancer
Open the PDF for Phase II Study of Imatinib in Patients with Small Cell Lung Cancer in another window
Journal Articles

Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors

Patricia M. LoRusso, Roy S. Herbst, Danny Rischin, Malcolm Ranson, Hilary Calvert, Eric Raymond, Dirk Kieback, Stan Kaye, Luca Gianni, Adrian Harris, Thomas Bjork, Anne-Marie Maddox, Mace L. Rothenberg, Eric J. Small, Eric H. Rubin, Andrea Feyereislova, Anne Heyes, Steven D. Averbuch, Judith Ochs, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (6): 2040–2048.
Published: 01 June 2003
View article titled, Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors
Open the PDF for Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors in another window